FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153872086> ?p ?o ?g. }

• W2153872086 endingPage "9" @default.
• W2153872086 startingPage "1021" @default.
• W2153872086 abstract "This study was conducted to identify tumor types warranting Phase II clinical trials of oxaliplatin using the human tumor cloning assay. Oxaliplatin was tested at concentrations ranging from 0.5 to 50.0 microg/ml in 1-h and 14-day continuous exposures along with 1.4 microg/ml carboplatin and 0.2 microg/ml cisplatin for comparison. We defined in vitro response as tumor growth inhibition >50% of control. In the 1-h exposure schedule, in vitro responses were observed in 9 of 116 (8%), 18 of 115 (16%), 38 of 103 (37%), and 7 of 13 (54%) tumor specimens at concentrations of 0.5, 5.0, 10.0, and 50.0 microg/ml oxaliplatin, respectively. In the 14-day exposure schedule, in vitro responses were observed in 10 of 121 (8%), 37 of 121 (31%), 57 of 106 (54%), and 15 of 15 (100%) tumor specimens at concentrations of 0.5, 5.0, 10.0, and 50.0 microg/ml oxaliplatin, respectively. Activity was observed against colon cancer, non-small cell lung cancer, gastric cancer, and melanoma colony-forming units. In both cisplatin-resistant and cisplatin-sensitive tumors, the activity of oxaliplatin was concentration and time dependent. A 1-h exposure to 5.0 and 10.0 microg/ml oxaliplatin led to 7.4 and 23.4% in vitro responses, respectively, in specimens resistant to 1-h exposure of 0.2 microg/ml cisplatin. Moreover, 1-h exposures to 5.0 microg/ml and 10.0 microg/ml oxaliplatin showed in vitro antitumor responses in 10.2 and 24.3%, 17.2 and 34.5%, 10.0 and 20.0%, 6.7 and 16.7%, and 11.4 and 34.3% of specimens resistant to 1.4 microg/ml carboplatin, 6.0 microg/ml 5-fluorouracil, 3.0 microg/ml irinotecan, 10.0 microg/ml paclitaxel, and 0.04 microg/ml doxorubicin, respectively. The effect in those drug-resistant specimens was improved when oxaliplatin was used on the protracted exposure regimen. Our data indicate that oxaliplatin is an active drug in vitro against a large variety of human tumors. Both concentration and duration of exposure are important factors for oxaliplatin cytotoxicity. The broad spectrum of activity and the in vitro activity against some tumors primarily resistant to conventional anticancer drugs encourage further clinical investigations of oxaliplatin in patients with advanced cancer refractory to conventional chemotherapy." @default.
• W2153872086 created "2016-06-24" @default.
• W2153872086 creator A5002864173 @default.
• W2153872086 creator A5013952219 @default.
• W2153872086 creator A5039359398 @default.
• W2153872086 creator A5052522275 @default.
• W2153872086 creator A5080900202 @default.
• W2153872086 date "1998-04-01" @default.
• W2153872086 modified "2023-10-18" @default.
• W2153872086 title "Activity of oxaliplatin against human tumor colony-forming units." @default.
• W2153872086 cites W119884028 @default.
• W2153872086 cites W1504583081 @default.
• W2153872086 cites W1537776971 @default.
• W2153872086 cites W1543404075 @default.
• W2153872086 cites W1619192225 @default.
• W2153872086 cites W1819328846 @default.
• W2153872086 cites W1820859680 @default.
• W2153872086 cites W1945650577 @default.
• W2153872086 cites W1963581476 @default.
• W2153872086 cites W1971367575 @default.
• W2153872086 cites W1975080796 @default.
• W2153872086 cites W1991055798 @default.
• W2153872086 cites W2004333543 @default.
• W2153872086 cites W2005428197 @default.
• W2153872086 cites W2019189272 @default.
• W2153872086 cites W2032146688 @default.
• W2153872086 cites W2032171886 @default.
• W2153872086 cites W2032553799 @default.
• W2153872086 cites W2033465919 @default.
• W2153872086 cites W2040094372 @default.
• W2153872086 cites W2042795561 @default.
• W2153872086 cites W2051703068 @default.
• W2153872086 cites W2052457410 @default.
• W2153872086 cites W2065982243 @default.
• W2153872086 cites W2078107516 @default.
• W2153872086 cites W2102455302 @default.
• W2153872086 cites W2115027988 @default.
• W2153872086 cites W2117500868 @default.
• W2153872086 cites W2780423151 @default.
• W2153872086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9563898" @default.
• W2153872086 hasPublicationYear "1998" @default.
• W2153872086 type Work @default.
• W2153872086 sameAs 2153872086 @default.
• W2153872086 citedByCount "23" @default.
• W2153872086 countsByYear W21538720862012 @default.
• W2153872086 countsByYear W21538720862013 @default.
• W2153872086 countsByYear W21538720862014 @default.
• W2153872086 countsByYear W21538720862015 @default.
• W2153872086 countsByYear W21538720862017 @default.
• W2153872086 countsByYear W21538720862020 @default.
• W2153872086 countsByYear W21538720862023 @default.
• W2153872086 crossrefType "journal-article" @default.
• W2153872086 hasAuthorship W2153872086A5002864173 @default.
• W2153872086 hasAuthorship W2153872086A5013952219 @default.
• W2153872086 hasAuthorship W2153872086A5039359398 @default.
• W2153872086 hasAuthorship W2153872086A5052522275 @default.
• W2153872086 hasAuthorship W2153872086A5080900202 @default.
• W2153872086 hasConcept C121608353 @default.
• W2153872086 hasConcept C126322002 @default.
• W2153872086 hasConcept C185592680 @default.
• W2153872086 hasConcept C202751555 @default.
• W2153872086 hasConcept C2776694085 @default.
• W2153872086 hasConcept C2777292972 @default.
• W2153872086 hasConcept C2778239845 @default.
• W2153872086 hasConcept C2780962732 @default.
• W2153872086 hasConcept C2781451048 @default.
• W2153872086 hasConcept C526805850 @default.
• W2153872086 hasConcept C55493867 @default.
• W2153872086 hasConcept C71924100 @default.
• W2153872086 hasConcept C98274493 @default.
• W2153872086 hasConceptScore W2153872086C121608353 @default.
• W2153872086 hasConceptScore W2153872086C126322002 @default.
• W2153872086 hasConceptScore W2153872086C185592680 @default.
• W2153872086 hasConceptScore W2153872086C202751555 @default.
• W2153872086 hasConceptScore W2153872086C2776694085 @default.
• W2153872086 hasConceptScore W2153872086C2777292972 @default.
• W2153872086 hasConceptScore W2153872086C2778239845 @default.
• W2153872086 hasConceptScore W2153872086C2780962732 @default.
• W2153872086 hasConceptScore W2153872086C2781451048 @default.
• W2153872086 hasConceptScore W2153872086C526805850 @default.
• W2153872086 hasConceptScore W2153872086C55493867 @default.
• W2153872086 hasConceptScore W2153872086C71924100 @default.
• W2153872086 hasConceptScore W2153872086C98274493 @default.
• W2153872086 hasIssue "4" @default.
• W2153872086 hasLocation W21538720861 @default.
• W2153872086 hasOpenAccess W2153872086 @default.
• W2153872086 hasPrimaryLocation W21538720861 @default.
• W2153872086 hasRelatedWork W112210410 @default.
• W2153872086 hasRelatedWork W2016660198 @default.
• W2153872086 hasRelatedWork W2035442859 @default.
• W2153872086 hasRelatedWork W2064648197 @default.
• W2153872086 hasRelatedWork W2093944971 @default.
• W2153872086 hasRelatedWork W2096211459 @default.
• W2153872086 hasRelatedWork W2100726270 @default.
• W2153872086 hasRelatedWork W2108081406 @default.
• W2153872086 hasRelatedWork W2415897764 @default.
• W2153872086 hasRelatedWork W4223553151 @default.
• W2153872086 hasVolume "4" @default.

• next